1. Home
  2. STEC vs BOLD Comparison

STEC vs BOLD Comparison

Compare STEC & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STEC
  • BOLD
  • Stock Information
  • Founded
  • STEC 2006
  • BOLD 2018
  • Country
  • STEC Hong Kong
  • BOLD United States
  • Employees
  • STEC N/A
  • BOLD N/A
  • Industry
  • STEC
  • BOLD
  • Sector
  • STEC
  • BOLD
  • Exchange
  • STEC NYSE
  • BOLD Nasdaq
  • Market Cap
  • STEC 29.7M
  • BOLD 24.4M
  • IPO Year
  • STEC 2021
  • BOLD 2024
  • Fundamental
  • Price
  • STEC $0.77
  • BOLD $1.18
  • Analyst Decision
  • STEC
  • BOLD Buy
  • Analyst Count
  • STEC 0
  • BOLD 3
  • Target Price
  • STEC N/A
  • BOLD $4.00
  • AVG Volume (30 Days)
  • STEC 15.6K
  • BOLD 276.3K
  • Earning Date
  • STEC 07-22-2025
  • BOLD 08-11-2025
  • Dividend Yield
  • STEC N/A
  • BOLD N/A
  • EPS Growth
  • STEC N/A
  • BOLD N/A
  • EPS
  • STEC N/A
  • BOLD N/A
  • Revenue
  • STEC $10,672,000.00
  • BOLD N/A
  • Revenue This Year
  • STEC $9,392.20
  • BOLD N/A
  • Revenue Next Year
  • STEC N/A
  • BOLD N/A
  • P/E Ratio
  • STEC N/A
  • BOLD N/A
  • Revenue Growth
  • STEC N/A
  • BOLD N/A
  • 52 Week Low
  • STEC $0.20
  • BOLD $1.00
  • 52 Week High
  • STEC $3.25
  • BOLD $4.72
  • Technical
  • Relative Strength Index (RSI)
  • STEC 38.95
  • BOLD N/A
  • Support Level
  • STEC $0.60
  • BOLD N/A
  • Resistance Level
  • STEC $0.88
  • BOLD N/A
  • Average True Range (ATR)
  • STEC 0.08
  • BOLD 0.00
  • MACD
  • STEC -0.01
  • BOLD 0.00
  • Stochastic Oscillator
  • STEC 47.40
  • BOLD 0.00

About STEC SANTECH HOLDINGS LIMITED

Santech Holdings Ltd is a customer based technology company. The company is engaged in exploring new opportunities in technology that includes new retail, social e-commerce, metaverse and others.

About BOLD Boundless Bio Inc. Common Stock

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Share on Social Networks: